Division of Epidemiology and Health Index, Center for Genome Science, Korea National Institute of Health, Cheongju-city, Republic of Korea; Division of Cardiovascular Diseases, Center for Biomedical Science, Korea National Institute of Health, Cheongju-city, Republic of Korea.
Division of Cardiovascular Diseases, Center for Biomedical Science, Korea National Institute of Health, Cheongju-city, Republic of Korea.
Maturitas. 2021 Apr;146:57-62. doi: 10.1016/j.maturitas.2021.02.003. Epub 2021 Feb 6.
The study aimed to evaluate the degree of menopausal hormonal therapy (MHT) use and the related trends, as well as the characteristics of Korean women who used MHT by type of hormone therapy.
Women aged ≥40 years were selected using data from the Korea National Insurance Service-National Sample Cohort 2002-2013 database. MHT entailed either estrogen therapy or estrogen plus progestogen therapy, as categorized by the Anatomical Therapeutic Chemical system. The prevalence of MHT use was calculated as the number of women with prescriptions annually and the level of hormone consumption was calculated using the defined daily dose (DDD).
The proportion of MHT users among women aged ≥40 years was 7.8 % in 2002, which decreased to 6.3 % in 2013. The overall MHT consumption level in 2002 was 27.5 DDDs/1000 inhabitants/day. There was a sharp decline in the first few years after 2002 and this value decreased to 12.5 DID in 2013; however, the decrease had lessened from 2006 to 2013 and differed by HT type, administration route, age, and income level. During the 11-year follow-up, over 70 % of women were prescribed MHT for less than 1 year, while only 11.8 % had a prescription for 3 years or more, and women who started treatment at age 45-59 years showed longer treatment duration.
Since 2002, MHT use among Korean women, especially overall MHT consumption, has declined remarkably. Regarding the pattern of use among women who took hormone preparations during 2002-2013, MHT was used around menopause, over the short term only, and at low dose.
本研究旨在评估韩国女性接受激素疗法（HT）的程度和相关趋势，以及不同 HT 类型的女性特征。
使用 2002-2013 年韩国国家健康保险服务-国家样本队列数据库的数据，选择年龄≥40 岁的女性。HT 包括雌激素治疗或雌孕激素联合治疗，按照解剖治疗化学系统分类。每年使用 MHT 的女性人数为 MHT 使用率，用定义日剂量（DDD）计算激素消耗量。
2002 年≥40 岁女性中 MHT 使用者的比例为 7.8%，到 2013 年降至 6.3%。2002 年总体 MHT 消费水平为 27.5 DDD/1000 居民/天。2002 年后的头几年急剧下降，这一数值在 2013 年降至 12.5 DDD；然而，从 2006 年到 2013 年，下降幅度有所减缓，并且因 HT 类型、给药途径、年龄和收入水平而异。在 11 年的随访期间，超过 70%的女性接受 MHT 的时间不足 1 年，只有 11.8%的女性开具了 3 年或以上的处方，而在 45-59 岁开始治疗的女性治疗时间更长。
自 2002 年以来，韩国女性接受 HT 的比例，尤其是总体 MHT 消费，显著下降。关于 2002-2013 年期间服用激素制剂的女性使用模式，HT 在接近绝经期、短期且低剂量使用。
